A Second View: Discussing the BTK inhibitor landscape for CLL and SLL with a focus on the Phase 3 AMPLIFY study of acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo

Executed on:Feb 5, 2025 5:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Mount Sinai

Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai.
Currently manages ~250 patients with CLL and SLL and 70 patients with Hodgkin Lymphoma.
Research areas of focus include Lymphoma immunotherapy and B-cell receptor signaling inhibitors (e.g. PI3K, mTOR, BTK)

Interview Goal

On this call we will be discussing the developing Bruton tyrosine kinase (BTK) inhibitor landscape for CLL and SLL with a primary focus on the recent data from the Phase 3 AMPLIFY study of Acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo presented at ASH 2024. We will also be discussing BTK Degraders NX-5948 vs. BGB-16673.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.